IGF-1 and Osteoporosis: Lessons from Mice and Men

  • Clifford J. Rosen
  • Leah Rae Donahue
  • Wesley G. Beamer
  • Robert A. Adler
  • Etah S. Kurland
  • John P. Bilezikian
Part of the Proceedings in the Serono Symposia USA Series book series (SERONOSYMP)


The insulin-like growth factors (IGF-1 and -2) are ubiquitous polypeptides that mediate the activity of growth hormone. In many tissues they serve as paracrine or autocrine factors (1). Second only to the liver, the skeleton is an exceptionally rich source of IGF-1 where it is both synthesized and stored. During bone remodeling, both systemic and skeletal IGF-1 play a major role in the recruitment and differentiation of osteoblasts (2, 3). In the course of bone resorption, the initiating bone remodeling event, matrix-bound IGFs are released and become critical coupling agents linking the processes of bone resorption and bone formation (2). Efforts to establish a relationship between synthesis of rapid bone loss or impaired bone formation and changes in the skeletal or circulatory IGF system have led to several hypotheses suggesting that IGF-1 is of pathophysiologic significance (2). Two recent studies, one showing an age-associated decline in skeletal IGF-1, and the other relating serum IGF-1 to bone density, have strengthened the view that the skeletal IGF regulatory system is important in states of impaired bone remodeling (4, 5). Two additional studies have demonstrated a strong relationship between serum IGF-1 and bone mineral density in men with idiopathic osteoporosis (6, 7). Based on these lines of evidence and the concept that bone density at any age is strongly dependent on peak bone mass, our group has considered IGF-1 to be a key factor in the acquisition of peak bone mass. In this paper, data will be presented which suggest that in several inbred strains of mice and in humans, osteoporotic male idiopathic IGF-1 is an important determinant of bone mineral density (BMD).


Bone Mineral Density Bone Mass Inbred Strain Peak Bone Mass Femoral Bone Mineral Density 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Jones JL, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995; 16: 3–32.PubMedGoogle Scholar
  2. 2.
    Rosen CJ, Donahue LR, Hunter SJ. IGFs and bone: the osteoporosis connection. Proc Soc Exp Biol Med 1994; 206: 83–102.PubMedGoogle Scholar
  3. 3.
    Hayden JM, Mohan S, Baylink DJ. The insulin-like growth factor system and the coupling of formation to resorption. Bone 1995; 17: 93–8S.CrossRefGoogle Scholar
  4. 4.
    Nicholas V, Prewett A, Bettica P, Mohan S, Finkleman RD, Baylink DJ, et al. Age-related decreases in IGF-1 and transforming growth factor-/3 in femoral cortical bone from both men and women: implications for bone loss in aging. J Clin Endocrinol Metab 1994; 78: 1011–6.CrossRefGoogle Scholar
  5. 5.
    Mohan S, Baylink DJ. Development of a simple valid method for the complete removal of IGF binding proteins from IGFs in human serum and other biological fluids: comparison with acid-ethanol treatment and C18 Sep-Pak separation. J Clin Endocrinol Metab 1995; 80: 637–47.PubMedCrossRefGoogle Scholar
  6. 6.
    Ljunghall S, Johansson AG, Buman P, Kampe O, Lindh E, Karlsson FA. Low plasma levels of IGF-1 in male patients with idiopathic osteoporosis. J Intern Med 1992; 232: 59–64.PubMedCrossRefGoogle Scholar
  7. 7.
    Reed BY, Zerwekh JE, Sakhaeek K, Breslau NA, Gottschalk F, Pak CYC. Serum IGF-1 is low and correlated with osteoblastic surface in idiopathic osteoporosis. J Bone Miner Res 1995; 10: 1218–24.PubMedCrossRefGoogle Scholar
  8. 8.
    Beamer WG, Donahue LR, Rosen CJ, Baylink DJ. Genetic variability in adult bone density among inbred strains of mice. Bone 1996; 18: 397–403.PubMedCrossRefGoogle Scholar
  9. 9.
    Jorgensen JOL, Thuesen L, Ingemann-Hansen T, Pedersen SA, Jorgensen JU, Skakkebaek NES, et al. Beneficial effects of GH treatment in GH deficient adults. Lancet 1989; 1: 1221–5.PubMedCrossRefGoogle Scholar
  10. 10.
    Donahue LR, Beamer WG, Rosen CJ. Parathyroid hormone improves bone density in mice with growth hormone deficiency and IGF-1 deficiency. J Bone Miner Res 1995; 10: 523.Google Scholar

Copyright information

© Springer-Verlag New York, Inc. 1998

Authors and Affiliations

  • Clifford J. Rosen
  • Leah Rae Donahue
  • Wesley G. Beamer
  • Robert A. Adler
  • Etah S. Kurland
  • John P. Bilezikian

There are no affiliations available

Personalised recommendations